Dissecting the Epigenetic Orchestra of HDAC Isoforms in Breast Cancer Development: a Review

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Nov 12

PMID 39532757

Authors

Maria Debbarma

Kakali Sarkar

Samir Kumar Sil

Affiliations

Soon will be listed here.

Abstract

Epigenetic modulators have recently emerged as potential targets in cancer therapy. Breast cancer, the second leading cause of cancer-related deaths among women globally and the most common cancer in India, continues to have a low survival rate despite available treatments. This underscores the urgent need for more effective therapeutic strategies. Histone deacetylases (HDACs), a prominent class of epigenetic modulators, are frequently overexpressed in various cancers, including breast cancer, making them and their downstream pathways, a focus of current research, aiming to develop more effective and less invasive treatments that could help overcome chemoresistance and enhance patient outcomes. Despite the growing body of evidences, a comprehensive and consolidated review on molecular intricacy behind the HDAC-mediated epigenetic regulation of breast cancer is conspicuously absent. Therefore, this review aims to open doors for future research by exploring the evolving role of HDACs, their molecular mechanisms, and their potential as therapeutic targets in breast cancer treatment.

References

Lima S, Kehm R, Terry M . Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021; 38:100985. PMC: 8271114. DOI: 10.1016/j.eclinm.2021.100985. View

Sopik V . International variation in breast cancer incidence and mortality in young women. Breast Cancer Res Treat. 2020; 186(2):497-507. DOI: 10.1007/s10549-020-06003-8. View

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M . Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022; 66:15-23. PMC: 9465273. DOI: 10.1016/j.breast.2022.08.010. View

Burguin A, Diorio C, Durocher F . Breast Cancer Treatments: Updates and New Challenges. J Pers Med. 2021; 11(8). PMC: 8399130. DOI: 10.3390/jpm11080808. View

Francies F, Hull R, Khanyile R, Dlamini Z . Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. Am J Cancer Res. 2020; 10(5):1568-1591. PMC: 7269781. View

Ji X, Lu Y, Tian H, Meng X, Wei M, Cho W . Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019; 114:108800. DOI: 10.1016/j.biopha.2019.108800. View

Kim A, Mo K, Kwon H, Choe S, Park M, Kwak W . Epigenetic Regulation in Breast Cancer: Insights on Epidrugs. Epigenomes. 2023; 7(1). PMC: 9953240. DOI: 10.3390/epigenomes7010006. View

Pramanik S, Halder A, Mukherjee U, Kumar D, Dey Y, R M . Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Front Chem. 2022; 10:948217. PMC: 9411967. DOI: 10.3389/fchem.2022.948217. View

Kuribayashi F, Nunoi H, Wakamatsu K, Tsunawaki S, Sato K, Ito T . The adaptor protein p40(phox) as a positive regulator of the superoxide-producing phagocyte oxidase. EMBO J. 2002; 21(23):6312-20. PMC: 136946. DOI: 10.1093/emboj/cdf642. View

10.

Martinez-Balbas M, Bauer U, Nielsen S, Brehm A, Kouzarides T . Regulation of E2F1 activity by acetylation. EMBO J. 2000; 19(4):662-71. PMC: 305604. DOI: 10.1093/emboj/19.4.662. View

11.

Yao Y, Yang W, Seto E . Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol. 2001; 21(17):5979-91. PMC: 87316. DOI: 10.1128/MCB.21.17.5979-5991.2001. View

12.

Lopez J, Haynes S, Majmudar J, Martin B, Fierke C . HDAC8 Substrates Identified by Genetically Encoded Active Site Photocrosslinking. J Am Chem Soc. 2017; 139(45):16222-16227. PMC: 5865639. DOI: 10.1021/jacs.7b07603. View

13.

Di Giorgio E, Brancolini C . Regulation of class IIa HDAC activities: it is not only matter of subcellular localization. Epigenomics. 2016; 8(2):251-69. DOI: 10.2217/epi.15.106. View

14.

Zhang H, Shang Y, Chen H, Li J . Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. 2016; 47(2):149-159. DOI: 10.1111/hepr.12757. View

15.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

16.

Garmpis N, Damaskos C, Dimitroulis D, Kouraklis G, Garmpi A, Sarantis P . Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer. J Pers Med. 2022; 12(10). PMC: 9604828. DOI: 10.3390/jpm12101672. View

17.

Rahbari R, Rasmi Y, Khadem-Ansari M, Abdi M . The role of histone deacetylase 3 in breast cancer. Med Oncol. 2022; 39(5):84. DOI: 10.1007/s12032-022-01681-4. View

18.

Li A, Chen P, Leng Y, Kang J . Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. Oncogene. 2018; 37(45):5952-5966. DOI: 10.1038/s41388-018-0379-9. View

19.

Rahmani G, Sameri S, Abbasi N, Abdi M, Najafi R . The clinical significance of histone deacetylase-8 in human breast cancer. Pathol Res Pract. 2021; 220:153396. DOI: 10.1016/j.prp.2021.153396. View

20.

Zucchetti B, Shimada A, Katz A, Curigliano G . The role of histone deacetylase inhibitors in metastatic breast cancer. Breast. 2018; 43:130-134. DOI: 10.1016/j.breast.2018.12.001. View